Say Goodbye to Monthly Fees With This 1TB Cloud Storage Plan
The following content is brought to you by PCMag partners. If you buy a product featured here, we may earn an affiliate commission or other compensation.
Paying for cloud storage every month can add up quickly, especially if you're managing large files or working across multiple devices. For anyone looking to replace ongoing subscription fees with a more permanent option, Koofr's 1TB lifetime plan is a practical alternative for only $119.97 (reg. $810).
Koofr is a straightforward cloud storage solution with lifetime access for a one-time fee. You'll get 1TB of space that works across devices, with support for WebDAV and easy access via mobile apps and desktop. It also integrates with other major cloud services like Google Drive, Dropbox, OneDrive, and Amazon, so you can manage multiple accounts from a single interface.
The platform includes helpful file management tools like a duplicate finder, advanced file renaming, and customizable link settings. Data is encrypted both in transit and at rest, and Koofr has a strict no-tracking policy, which sets it apart from many free or ad-supported services.
Koofr isn't a full replacement for enterprise-grade platforms, but it offers solid reliability and control for personal or small team use. The interface is clean and easy to use, with no unnecessary features getting in the way. If you're looking for long-term storage without the commitment of another monthly bill, this plan offers a simple, scalable solution. For tech-savvy users who prefer to own their tools over renting them, Koofr is worth a look.
Use code KOOFR to get a Koofr Cloud Storage 1TB subscription on sale for $119.97 (reg $810).
Prices subject to change. PCMag editors select and review products independently. If you buy through StackSocial affiliate links, we may earn commissions, which help support our testing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Dollar tumbles, Japan trade tensions, European bank rally: 3 Things
Here are three of the top stories Wall Street is watching on Tuesday, July 1. The dollar (DX=F, is at its weakest start to a year since 1973, hitting a 10-year low against the yen and nearing a four-year low against the euro (EUR=X). Trade tensions with Japan are heating up ahead of a July 9 deadline, with the US threatening tariffs and Japan defending its agricultural sector. European banks just posted their best first-half performance since 1997, with France's Societe Generale ( leading gains. To watch more expert insights and analysis on the latest market action, check out more Morning Brief: Market Sunrise here. These are the things you need to know before that opening bell rings. Firstly, we're going to focus on the dollar. We know that it's had its worst start to the year since 1973, and today it's weaker again. In fact, the dollar's trading at multi-year lows against most major currencies. Against the euro, it's near a four-year low, and against the Japanese yen, it hit a 10-year low earlier. The greenback's weakness has partially been driven by worries over President Trump's massive tax cut and spending bill and the increase in the amount of debt the US faces as a result. Secondly, let's look at trade negotiations and Japan. Remember, the deadline for negotiations is July 9th. While on Truth Social, the president zeroed in on rice. He said that Japan had a shortage but wouldn't take American rice. The White House has said that it will send letters, which sets out tariff rates to the countries it believes haven't come to the negotiations in good faith. For its part, Japan said it will not sacrifice its agricultural sector in the talks. If a deal is not reached, it could have a massive impact on many sectors in Japan, but in particular, the car industry there. And finally, let's turn to Europe and their banks. Stocks in this sector there have just completed their best first half performance since 1997. The STOXX 600 Bank Index was up almost 30%. They've all been boosted by strong returns and resilient earnings. Leading the gains is France's Société Générale, up about 78% this year alone. Its new CEO has a turnaround plan that seems to be working. He's focused on leaving non-core businesses, boosting the balance sheet, lifting its profit targets, and also shareholder returns. But there have been winners on Wall Street, too, over the first six months of 2025, as well. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN Non-dilutive financing further strengthens Apellis' balance sheet Apellis retains full U.S. commercialization rights for systemic pegcetacoplan Transaction underscores shared confidence in the meaningful growth potential in rare kidney diseases WALTHAM, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300 million in exchange for 90% of Apellis' future ex-U.S. royalties for Aspaveli® (systemic pegcetacoplan). Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI®. 'This transaction reflects our shared conviction in the potential of Aspaveli/EMPAVELI to transform the treatment landscape for patients with rare diseases, including C3G and IC-MPGN,' said Timothy Sullivan, chief financial officer, Apellis. 'Through our collaboration, Sobi has developed a deep understanding of Aspaveli/EMPAVELI's potential to significantly improve patient outcomes and deliver long-term value as a rare disease franchise. Importantly, the non-dilutive funding from this transaction further strengthens our balance sheet and provides significant operational flexibility as we approach sustainable profitability, expand the reach of our approved products, and advance our innovative pipeline.' Aspaveli/EMPAVELI is approved in the European Union, other countries globally, and the U.S. for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It is currently under review in the European Union and the U.S. for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare kidney diseases. An opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) is expected before year-end. In the U.S., the Prescription Drug User Fee Act (PDUFA) action date is July 28, 2025. 'We are pleased to reaffirm our ongoing partnership with Apellis and share their strong belief in Aspaveli/EMPAVELI's potential to deliver significant long-term growth,' said Guido Oelkers, chief executive officer, Sobi. 'We are confident in our ability to reach patients with C3G and IC-MPGN globally following regulatory approvals, by leveraging our broad commercial footprint, deep rare disease expertise, and proven success in PNH.' Transaction details Under the terms of the agreement, Sobi will acquire 90% of Apellis' ex-U.S. royalties for Aspaveli for $275 million in cash. Apellis will also be eligible for up to $25 million in milestone payments upon EMA approval of Aspaveli for C3G and IC-MPGN. The agreement is subject to defined caps tied to Aspaveli's performance. Sobi retains 90% of ex-U.S. royalties until these caps are achieved, after which 100% of all ex-U.S. royalties revert to Apellis. About the Apellis and Sobi CollaborationApellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialization. Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. About C3 Glomerulopathy (C3G) and Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3G and primary IC-MPGN are rare and debilitating kidney diseases that can lead to kidney failure. Excessive C3 deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. Approximately 50% of people living with C3G and primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis.1 Additionally, approximately 90% of patients who previously received a kidney transplant will experience disease recurrence.2 The diseases are estimated to affect 5,000 people in the United States and up to 8,000 in Europe.3 About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on X and LinkedIn. Apellis Forward-Looking Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding regulatory approval for the treatment of patients with C3G and IC-MPGN in the United States and other jurisdictions and commercial growth or prospects for systemic pegcetacoplan for those indications in the United States and other jurisdictions. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether systemic pegcetacoplan will receive approval for those indications from the FDA or equivalent foreign regulatory agencies when expected or at all; whether the commercialization of systemic pegcetacoplan for C3G or IC-MPGN in the United States or other jurisdictions will provide significant additional revenues or allow the Company to achieve profitability; and any other factors discussed in the 'Risk Factors' section of Apellis' Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2025 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contacts: MediaTracy Vineismedia@ InvestorsNeil Carnahan, CFA References1. C3 glomerulopathy. National Institute of Health, Genetics Home Reference. Accessed November 21, 2019. 2. Tarragón, B, et al. C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation. Clinical Journal of the American Society of Nephrology. August 2024; 19(8)1005-1015. doi: 10.2215/CJN.0000000000000474.3. Data on file using literature in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Riverwater Partners Sustainable Value Strategy Increased its Stake in Antero Midstream Corp (AM)
Riverwater Partners, an investment management company, released its 'Sustainable Value Strategy' Q1 2025 investor letter. A copy of the letter can be downloaded here. The strategy outperformed its benchmark, the Russell 2500 Value Index, in the first quarter. The relative outperformance was primarily driven by positive stock selection, while the allocation effect also contributed positively. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, Riverwater Partners Sustainable Value Strategy highlighted stocks such as Antero Midstream Corporation (NYSE:AM). Antero Midstream Corporation (NYSE:AM) owns, operates, and develops midstream energy assets. The one-month return of Antero Midstream Corporation (NYSE:AM) was -0.21%, and its shares gained 29.26% of their value over the last 52 weeks. On June 30, 2025, Antero Midstream Corporation (NYSE:AM) stock closed at $18.95 per share, with a market capitalization of $9.081 billion. Riverwater Partners Sustainable Value Strategy stated the following regarding Antero Midstream Corporation (NYSE:AM) in its Q1 2025 investor letter: "During the quarter, we increased our exposure to the energy transition by adding Range Resources (RRC) and Antero Midstream Corporation (NYSE:AM) to our portfolio. Both companies play critical roles in energy and electrification. Electrification is expected to see significant demand growth in the coming years and decades. A long pipeline snaking through a rural landscape - symbolizing the companies midstream energy services. Antero Midstream Corporation (NYSE:AM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held Antero Midstream Corporation (NYSE:AM) at the end of the first quarter, which was 38 in the previous quarter. While we acknowledge the potential of Antero Midstream Corporation (NYSE:AM) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Antero Midstream Corporation (NYSE:AM) and shared the list of stocks to buy from Goldman Sachs energy stocks. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. While we acknowledge the potential of AM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
